References
- Sundhedsdatastyrelsen. Nye Kraefttilfaelde i Danmark 2016. Cancerregisteret2017.
- Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;1:96–108.
- Huang GJ, Stein JP. Open radical cystectomy with lymphadenectomy remains the treatment of choice for invasive bladder cancer. Curr Opin Urol. 2007;17:369–375.
- International Collaboration of T, Medical Research Council Advanced Bladder Cancer Working P, European Organisation for R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171–2177.
- Collaboration ABCM-a. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361:1927–1934.
- Soloway MS, Ikard M, Ford K. Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer. Cancer. 1981;47:476–480.
- Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378.
- Hansen E, Larsson H, Norgaard M, et al. The Danish bladder cancer database. Clep. 2016;8:439–443.
- Chang SS, Bochner BH, Chou R, et al. Treatment of Non-Metastatic muscle-invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline: American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO); 2017. Available from: https://www.auanet.org/guidelines/bladder-cancer-non-metastatic-muscle-invasive-guideline
- Witjes (Chair) MB JA, Compérat E, Cowan NC, et al. Muscle-invasive and Metastatic Bladder Cancer, European Association of Urology (EAU) Guidelines 2018. Available from: http://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/#7
- DaBlaCa. Nationale Kliniske Retningslinier for Behandling af Blaeretumorer i Danmark 2017. Available from: http://skejby.net/Webudgaven/DaBlaCa2010.htm
- Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol. 2004;45:297–303.
- Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–866.
- Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet. 1999;354:533–540.
- Schiffmann J, Sun M, Gandaglia G, et al. Suboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: a population-based study. CUAJ. 2016;10:82–86.
- Hermans TJN, Fransen van de Putte EE, Horenblas S, et al. Perioperative treatment and radical cystectomy for bladder cancer–a population based trend analysis of 10,338 patients in the Netherlands. Eur J Cancer. 2016;54:18–26.
- Reardon ZD, Patel SG, Zaid HB, et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol. 2015;67:165–170.
- Jerlstrom T, Gardmark T, Carringer M, et al. Urinary bladder cancer treated with radical cystectomy: perioperative parameters and early complications prospectively registered in a national population-based database. Scand J Urol. 2014;48:334–340.
- Davis K. The Danish health system through an American lens. Health Policy. 2002;59:119–132.
- Black PC, Brown GA, Dinney CP. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol. 2009;27:3–7.
- Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152–165.